Apixaban (Eliquis®, Bristol-Myers Squibb GmbH & Co. KGaA/Pfizer Pharma GmbH) is a factor Xa (FXa) inhibitor anticoagulant indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation and for prophylaxis and treatment of deep vein thrombosis and pulmonary embolism. The gene discussed is F10; the disease is stroke disorder.